Related Experiment Videos
Urotensin-II receptor peptide agonists
Alfonso Carotenuto1, Paolo Grieco, Ettore Novellino
1Department of Pharmaceutical Sciences, University of Salerno, I-84084 Fisciano, Italy.
Medicinal Research Reviews
|June 30, 2004
Summary
Urotensin II (U-II), a fish hormone, is the ligand for a human G-protein-coupled receptor (GPCR) linked to cardiovascular diseases. Research focuses on its C-terminal cyclic peptide for developing new therapeutic analogues.
Area of Science:
- Biochemistry
- Pharmacology
- Endocrinology
Background:
- Urotensin II (U-II) is a teleost fish hormone recently identified as the endogenous ligand for a human G-protein-coupled receptor (GPCR), homologous to rat GPR14.
- Human U-II is a potent vasoconstrictor with widespread tissue distribution, implicated in various human cardiovascular diseases.
- Its C-terminal cyclic hexapeptide (Cys-Phe-Trp-Lys-Tyr-Cys) is crucial for bioactivity, with the Trp-Lys-Tyr motif being a key determinant.
Purpose of the Study:
- To investigate the structure-activity relationships of Urotensin II (U-II) and its receptor.
- To utilize the U-II C-terminal cyclic portion as a template for developing novel synthetic analogues.
- To facilitate the design of potent and selective agonists or antagonists for the human U-II receptor.
Main Methods:
- Structure-activity relationship (SAR) studies focused on the C-terminal cyclic hexapeptide of U-II.
- Development of synthetic analogues based on the U-II cyclic peptide template, including the superagonist P5U.
- Conformational studies to understand the role of the hU-II C-terminal cyclic portion and build 3D pharmacophore models.
Main Results:
- The C-terminal cyclic hexapeptide, particularly the Trp-Lys-Tyr motif, is critical for U-II bioactivity.
- A superagonist analogue, P5U, was developed.
- Conformational studies confirmed the importance of the cyclic portion, enabling the creation of 3D pharmacophore models.
Conclusions:
- The C-terminal cyclic portion of Urotensin II (U-II) is essential for its biological activity.
- Pharmacophore models derived from U-II structure can guide the development of new receptor ligands.
- Further research into U-II analogues may lead to novel therapeutics for cardiovascular diseases and a better understanding of U-II's physiological role.